These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31563516)

  • 1. Comparison of anti-inflammatory mechanisms between doxofylline and theophylline in human monocytes.
    Talmon M; Massara E; Brunini C; Fresu LG
    Pulm Pharmacol Ther; 2019 Dec; 59():101851. PubMed ID: 31563516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxofylline does not increase formoterol-induced cAMP nor MKP-1 expression in ASM cells resulting in lack of anti-inflammatory effect.
    Patel BS; Kugel MJ; Baehring G; Ammit AJ
    Pulm Pharmacol Ther; 2017 Aug; 45():34-39. PubMed ID: 28414142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of doxofylline in asthma and COPD.
    Cazzola M; Matera MG
    Respir Med; 2020 Apr; 164():105904. PubMed ID: 32094104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse.
    Riffo-Vasquez Y; Man F; Page CP
    Pulm Pharmacol Ther; 2014 Apr; 27(2):170-8. PubMed ID: 24456641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma -- a double-blind randomized placebo-controlled multicentre clinical trial.
    Goldstein MF; Chervinsky P
    Med Sci Monit; 2002 Apr; 8(4):CR297-304. PubMed ID: 11951074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid sparing effects of doxofylline.
    Riffo-Vasquez Y; Venkatasamy R; Page CP
    Pulm Pharmacol Ther; 2018 Feb; 48():1-4. PubMed ID: 29031617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxofylline and theophylline are xanthines with partly different mechanisms of action in animals.
    Franzone JS; Cirillo R; Barone D
    Drugs Exp Clin Res; 1988; 14(7):479-89. PubMed ID: 3240706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxofylline, an adenosine-nonblocking xanthine, does not induce cardiostimulant effects.
    Cirillo R; Grossi E; Franzone JS
    Res Commun Chem Pathol Pharmacol; 1989 Jul; 65(1):21-34. PubMed ID: 2781149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease.
    Lal D; Manocha S; Ray A; Vijayan VK; Kumar R
    J Basic Clin Physiol Pharmacol; 2015 Sep; 26(5):443-51. PubMed ID: 25894641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis.
    Rogliani P; Calzetta L; Ora J; Cazzola M; Matera MG
    Multidiscip Respir Med; 2019; 14():25. PubMed ID: 31388422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxofylline is not just another theophylline!
    Matera MG; Page C; Cazzola M
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3487-3493. PubMed ID: 29255355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease.
    Shukla D; Chakraborty S; Singh S; Mishra B
    Expert Opin Pharmacother; 2009 Oct; 10(14):2343-56. PubMed ID: 19678793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxofylline differs from methylxanthines in its movement of cytosolic calcium.
    Franzone JS; Cirillo R; Reboani MC
    Int J Tissue React; 1991; 13(3):131-8. PubMed ID: 1960014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of moderate chronic obstructive pulmonary disease (stable) with doxofylline compared with slow release theophylline--a multicentre trial.
    Santra CK
    J Indian Med Assoc; 2008 Dec; 106(12):791-2, 794. PubMed ID: 19370950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylxanthine drug therapy in chronic heart failure associated with hypoxaemia: double-blind placebo-controlled clinical trial of doxofylline versus theophylline and bamifylline.
    Dini FL; Pasini G; Cortellini G; Cani E; Bettini R; Garagnani A; Gobbi G; Greco A; Onorato G; Pasini P
    Int J Clin Pharmacol Res; 1993; 13(6):305-16. PubMed ID: 8088931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).
    Calzetta L; Hanania NA; Dini FL; Goldstein MF; Fairweather WR; Howard WW; Cazzola M
    Pulm Pharmacol Ther; 2018 Dec; 53():20-26. PubMed ID: 30219705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism.
    van Mastbergen J; Jolas T; Allegra L; Page CP
    Pulm Pharmacol Ther; 2012 Feb; 25(1):55-61. PubMed ID: 22138191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxofylline: a "novofylline".
    Page CP
    Pulm Pharmacol Ther; 2010 Aug; 23(4):231-4. PubMed ID: 20380886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of doxofylline in COPD: A pairwise meta-analysis.
    Cazzola M; Calzetta L; Rogliani P; Page C; Matera MG
    Pulm Pharmacol Ther; 2018 Aug; 51():1-9. PubMed ID: 29705620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of theophylline and doxofylline on airway responsiveness in beagles].
    Sugeta A; Imai T; Idaira K; Horikoshi S; Okamoto M; Adachi M
    Arerugi; 1997 Jan; 46(1):7-15. PubMed ID: 9078607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.